ArticleFrontiers in oncology2025
Stereotactic total ablative radiotherapy with MR-LINAC for synchronous oligometastatic prostate cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Outcome after primary directed radiotherapy in predominantly PSMA-PET/CT-staged patients with metastatic prostate cancer.EJNMMI research · 2026Article
- MR-Linac-Based SBRT for Prostate Cancer: Dosimetric Benefits for Urethral Sparing Compared to VMAT and Tomotherapy.Cancers · 2026Article
- Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To prospectively investigate the feasibility, toxicity, and preliminary clinical outcomes of magnetic resonance (MR)-guided stereotactic total ablative radiotherapy (MRgSTAR) for simultaneous treatment of the prostate and pelvic bone metastases in patients with synchronous oligometastatic prostate cancer (OMPC). Methods: This study included patients with histologically confirmed synchronous OMPC, defined as ≤ 5 lymph node or pelvic bone metastases identified via prostate-specific membrane antigen positron emission tomography (PSMA-PET). Real-time adaptive MRgSTAR was delivered using a 1.5T MR-integrated linear accelerator (MR-LINAC) in five fractions, administered twice weekly, targeting the prostate (33.5-40 Gy) and nodal/bone metastases (36.5-40 Gy) simultaneously. Androgen-deprivation therapy (ADT) was initiated prior to MRgSTAR, with the addition of androgen receptor pathway inhibitor (ARPI) at the physician's discretion. Adverse events (AEs) were assessed using the Common Terminology Criteria for AEs v5.0, and tumor response was evaluated per the Response Evaluation Criteria in Solid Tumors v1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, with log-rank tests used to explore clinical factors associated with survival outcomes. Results: Forty-three patients underwent MRgSTAR, with a median follow-up of 36.5 months (range: 15.4-57.6 months). ADT combined with ARPI therapy was administered in 22 patients (52%). All patients completed the five-fraction regimen. Biochemical progression occurred in three patients, of whom two had out-of-field metastases and one had local progression as per follow-up PSMA-PET. The estimated 3-year OS and PFS rates were 100% and 95.2% (95% confidence interval: 89.0%-100%), respectively. No clinical factors, including ARPI use, significantly correlated with survival outcomes. No radiotherapy-related AEs of grade ≥ 3 were observed. Conclusion: MRgSTAR demonstrates promising early survival outcomes and a favorable toxicity profile in synchronous OMPC, warranting further investigation to confirm its therapeutic role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.